Nitric oxide (NO) produced by endothelial nitric oxide synthase (eNOS) is a potent vasodilator. Several polymorphisms in the eNOS gene have been described, some of them being linked with the increased risk of cardiovascular disease, coronary heart disease (CHD), and coronary spasm.
Methods and Results
We studied 3 polymorphisms within the gene of eNOS (-786T/C, G10T, and 894 G/T) in patients with their first myocardial infarction (MI) younger than 45 years and in healthy volunteers. We found the relation between the occurrence of eNOS 894G allele and the Gensini score, which describes the severity of CHD (P = .020).
Conclusions
The fact that first clinical manifestation of MI occurred in G carriers when the atherosclerotic plaque was much more advanced than in T carriers may suggest that wild-type genotype provided a better compensatory mechanisms due to NO synthesis and/or release. The polymorphisms within eNOS gene G10T, 894G/T, and −786T/C were not associated with the increased risk of MI.
KowalskiJ., BarylskiM., BanachM., GrycewiczJ., IrzmanskiR., PawlickiL.Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention.J Cardiovasc Pharm.2006; 48(4): 143–147.
2.
WinkelmannB.R., HagerJ., KrausW.E.Genetics of coronary heart disease: current knowledge and research principles.Am Heart J.2000; 140(4): S11–S26.
3.
KelmM.Significance of vascular nitric oxide synthase pathways in coronary artery disease. A multiple-level biomarker strategy.J Am Coll Cardiol.2006; 48(6): 1175–1176.
4.
RiosD.L., D'OnofrioL.O., SouzaJ.K.Smoking-dependent and haplotype-specific effects of endothelial nitric oxide synthase gene polymorphisms on angiographically assessed coronary artery disease in Caucasian- and African-Brazilians.Atherosclerosis.2007; 193(1): 135–141.
5.
CelermajerD.S., SorensenK.E., SpiegelhalterD.J., GeorgakopoulosD., RobinsonJ., DeanfieldJ.E.Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women.J Am Coll Cardiol.1994; 24(2): 471–476.
6.
GochA., BanachM., MikhailidisD.P., RyszJ., GochJ.H.Endothelial dysfunction in patients with noncomplicated and complicated hypertension.Clin Exp Hyper-tens.2009; 31(1): 20–30.
7.
HeitzerT., SchlinzigT., KrohnK., MeinertzT., MünzelT.Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease.Circulation.2001; 104(22): 2673–2678.
8.
AntoniadesC., TousoulisD., VasiliadouC.Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction (abstract).J Am Coll Cardiol.2005; 46(6): 1101–1109.
9.
MorrayB., GoldenbergI., MossA.J.Polymorphisms in the paraoxonase and endothelial nitric oxide synthase genes and the risk of early-onset myocardial infarction.Am J Cardiol.2007; 99(8): 1100–1105.
10.
IrokawaM., NishinagaM., FunayamaH., ShimadaK.The effect of endothelium-derived relaxing factor (EDRF) on anticoagulant heparan sulfate on cultured vascular endothelial cell (EC).Circulation.1994; 90(5): I–396.
11.
HuangP.L., HuangZ., MashimoH.Hypertension in mice lacking the gene for endothelial nitric oxide synthase.Nature.1995; 377(6546): 239–242.
12.
SchmidtH.H., WalterU.NO at work.Cell.1994; 78(6): 919–925.
LeeC.R., NorthK.E., BrayM.S.NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: the atherosclerosis risk in communities study.Pharmacogenet Genomics.2006; 16(12): 891–899.
15.
GuzikT.J., BlackE., WestN.E.Relationship between the G894T polymorphism (Glu 298Asp variant) in endothelial nitric oxide synthase and nitric oxide mediated endothelial function in human atherosclerosis.Am J Med Genetics.2001; 100(2): 130–137.
16.
Al SuwaidiJ., HamasakiS., HiganoS.T., NishimuraR.A., HolmesDRJr., LermanA.Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.Circulation.2000; 101(9): 948–954.
17.
FörstermannU., BoisselJ.P., KleinertH.Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III).FASEB J.1998; 12(10): 773–790.
18.
CookS.Coronary artery disease, nitric oxide and oxidative stress: the “Yin-Yang” effect—a Chinese concept for a worldwide pandemic.Swiss Med Wkly.2006; 136(7–8): 103–113.
19.
WhiteC.R., BrockT.A., ChangL.Y.Superoxide and peroxynitrite in atherosclerosis.Natl Acad Sci U S A.1994; 91(3): 1044–1048.
20.
BeckmanJ.S., BeckmanT.W., ChenJ., MarshallP.A., FreemanB.A.Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.Proc Natl Acad Sci U S A.1990; 87(4): 1620–1624.
21.
RiosD.L., Callegari-JacquesS.M., HutzM.H.Endothelial nitric oxide synthase and fractalkine chemokine receptor polymorphisms on angiographically assessed coronary atherosclerosis.Clin Chim Acta.2005; 362(1–2): 138–146.
22.
AlvarezR., GonzalesP., BatallaA.Association between the NOS3 (-786T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease.Nitric Oxide.2001; 5(4): 343–349.
YoshimuraM., YasueH., NakayamaM.Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T786C and missense Glu298Asp variants.J Investig Med.2000; 48(5): 367–374.
25.
MiyamotoY., YoshihikoS., KajiyamaM.Endothelial nitric oxide synthase gene is positively associated with essential hypertension.Hypertension.1998; 32(1): 3–8.
26.
GommaA.H., ElrayessM.A., KnightC.J., HaweE., FoxK.M., HumphriesS.E.The endothelial nitric oxide synthase (Glu298Asp and ‒786T/C) gene polymorphisms are associated with coronary in-stent restenosis.Eur Heart J.2002; 23(24): 1955–1962.
27.
JeerooburkhanN., JonesL.C., BujacS.Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease.Hypertension.2001; 38(5): 1054–1061.
28.
HingoraniA.D., JiaH., StevensP.A., MonteithM.S., BrownM.J.A common variant in exon 7 of the endothelial constitutive nitric oxide synthase gene.Clin Sci.1995; 88: 21P.
29.
PoirierO., MaoC., MalletC.Polymorphisms of the endothelial nitric oxide synthase gene: no consistent association with myocardial infarction in ECTIM study.Eur J Clin Invest.1999; 29(4): 284–290.
30.
BonnardeauxA., NadaudS., CharruA., JeunemaitreX., CorvolP., SoubrierF.Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension.Circulation.1995; 91(1): 96–102.
31.
MiyamotoY., SaitoY., NakayamaM.Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a 786T/C mutation associated with coronary spastic angina.Hum Mol Genet.2000; 9(18): 2629–2637.
32.
NakayamaM., YasueH., YoshimuraM.T-786C mutation in the 5'-flanking region of the enothelial nitric oxide synthase gene is associated with coronary spasm.Circulation.1999; 99(22): 2864–2870.
33.
CattaruzzaM., GuzikT.J., SlodowskiW.Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease.Circ Res.2004; 95(8): 841–847.
34.
SenthilD., RaveendranM., ShenY.H.Genotypedependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells.DNA Cell Biol.2005; 24(4): 218–224.
35.
TesauroM., ThompsonW.C., RoglianiP., QiL., ChaudharyP.P., MossJ.Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298.Proc Natl Acad Sci U S A.2000; 97(6): 2832–2835.
36.
GolserR., GorrenA.C., MayerB., SchmidtK.Functional characterization of Glu298Asp mutant human endothelial nitric oxide synthase purified from a yeast expression system.Nitric Oxide.2003; 8(1): 7–14.
37.
McDonaldD.M., AlpN.J., ChannonK.M.Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells.Pharmacogenetics.2004; 14(12): 831–839.
38.
JoshiM.S., MineoC., ShaulP.W., BauerJ.A.Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear.FASEB J.2007; 21(11): 2655–2663.
RossiG.P., CesariM., ZanchettaM.The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study.J Am Coll Cardiol.2003; 41(6): 930–937.
41.
SetoguchiS., HirookaY., EshimaK., ShimokawaH., TakeshitaA.Tetrahydrobiopterin improves impaired endothelium-dependent forearm vasodilation in patients with heart failure.J Cardiovasc Pharmacol.2002; 39(3): 363–368.
42.
DerebeckaN., HołyszM., DankowskiR., WierzchowieckiM., TrzeciakW.H.Polymorphism in intron 23 of the endothelial nitric oxide synthase gene (NOS3) is not associated with hypertension.Acta Biochimica Polonica.2008; 49(1): 263–268.
43.
The Joint European Society of Cardiology/American College of Cardiology Committee.Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction The Joint European Society of Cardiology/American College of Cardiology Committee.Eur Heart J.2000; 21(18): 1502–1503.
44.
GensiniG.G.A more meaningful scoring system for determining the severity of coronary heart disease.Am J Cardiol.1983; 51(3): 606.
45.
SambrookJ.E., FritschF., ManiatisT.Molecular Cloning: A Laboratory Manual.New York: Cold Spring Harbor; 1989.
46.
YeS., DhillonS., KeX., CollinsA.R., DayI.N.M.An efficient procedure for genotyping single nucleotide polymorphisms.Nucleic Acids Res.2001; 29(17): e88.
47.
BarylskiM., KowalczykE., BanachM., CiećwierzJ., PawlickiL., KowalskiJ.Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome.Angiology.2009; 60(1): 87–92.
48.
LipG.Y.H., RayK.K., ShiuM.F.Coronary spasm in acute “ myocardial infarction. Case report.Heart.1998; 80(2): 197–199.
49.
HorimotoM., TakenakaT., IgarashiK., FujiwaraM., BatraS.Coronary spasm as a cause of coronary thrombosis and myocardial infarction.Jpn Heart J.1993; 34(5): 627–631.
50.
TomonagaG.A study of angina pectoris due to coronary spasm in clinic cases.J Japan Physicians Assoc.2006; 20(3): 566–570.
51.
HingoraniA.D.Polymorphisms in endothelial nitric oxide synthase and atherosclerosis: John French Lecture 2000.Atherosclerosis.2001; 154(3): 521–527.
GodfreyV., ChanS.L., CassidyA.The functional consequence of the glu298asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers.Cardiovasc Drug Rev.2007; 25(3): 280–288.
HingoraniA.D., LiangC.F., FatibeneJ., LyonA., MonteithS., ParsonsA.A common variant of the endothelial nitric oxide synthase (Glu298 ? Asp) is a major risk factor for coronary artery disease in the UK.Circulation.1999; 100(14): 1515–1520.
57.
RossiG.P., MaiolinoG., ZanchettaM.The T786C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high–risk patients.J Am Coll Cardiol.2006; 48(6): 1166–1174.
58.
NakayamaM., YasueH., YoshimuraM.T-786C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis.Am J Cardiol.2000; 86(6): 628–34.
59.
YoonY., SongJ., HongS.H., KimJ.Q.Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease.Clin Chem.2000; 46(10): 1626–1630.
60.
HeuschP., SkyschallyA., LeineweberK., HaudeM., ErbelR., HeuschG.The interaction of coronary microembolization and ischemic preconditioning: a third window of cardioprotection through TNF-alpha.Arch Med Sci.2007; 3(2): 83–92.
61.
OkonskiP., BanachM., RyszJ.L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury.Ann Transplant.2006; 11(1): 26–32.
62.
KolovouG., DaskalovaD., MikhailidisD.P.Apolipoprotein E polymorphism and atherosclerosis.Angiology.2003; 54(1): 59–71.
63.
PiestrzeniewiczK., ŁuczakK., MaciejewskiM., GochJ.H.Impact of obesity and adipokines on cardiac structure and function in men with first myocardial infarction.Arch Med Sci.2008; 4(2): 152–160.
64.
BanachM., RyszJ., GochA., MikhailidisD.P., RosanoG.M.The role of trimetazidine after acute myocardial infarction.Curr Vascul Pharamacol.2008; 6(4): 282–291.
